Results were compiled and analyzed in Microsoft Excel (Redmond, Washington). The result reporting form also included fields for method and manufacturer codes. A reporting field for titer results was also available for each antibody class and instructions were given to use this reporting field only for neutralization assays. Reporting fields for qualitative and quantitative (ie, numeric values such as signal to cutoff ratio or index value) results were available for total antibody, IgG, IgM, and IgA.

Laboratories were instructed to perform serology testing by using the methodology routinely performed on clinical specimens and report the results to the CAP by July 14, 2020. Each laboratory received a 0.5-mL aliquot for each sample, sent in an insulated container with a cool pack and instructions to store samples at 2☌ to 8☌ until testing could be performed. Three individual samples, each from single donors, (2 that pretested positive and 1 negative) were sent to 1195 subscribing laboratories on June 22, 2020, along with kit instructions and the result reporting form. In addition, there is variation in the viral epitope used for antibody detection, with most assays targeting some portion of the SARS-CoV-2 spike (S) envelope glycoprotein or nucleocapsid (N) protein.ĭata were collected from the initial CAP SARS-CoV-2 Serology Survey (COVS-A 2020). 1, 2 Many commercial assays and laboratory-developed tests have been designed that use different detection methodologies (eg, lateral flow immunoassays, enzyme-linked immunosorbent assays, chemiluminescent immunoassays) to measure antibody isotypes (ie, discrete immunoglobulin G, IgM, and/or IgA assays) or combinations of isotypes (ie, total antibody assays). Detection of antibodies against SARS-CoV-2 antigens has become an important component in the fight against coronavirus disease 2019 (COVID-19), playing a role in seroprevalence studies, identifying therapeutic plasma units, assessing multisystem inflammatory syndrome in children and, in the future, potentially for monitoring vaccine responses. The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was met by a rapid response from clinical laboratories and manufacturers of in vitro diagnostic assays.

Coolpack 2 fisher